Find a Research Expert

Experts
 Menu

Lorraine O'Driscoll

Institution

Trinity College Dublin

Contact

Subjects

Biochemistry

Medicine & Nursing

Details
Publications 164
As first author 91
As last author 97
Unique topics 775
Collaborations 87
Patents 1
Sources 10
Are you Lorraine O'Driscoll? Click here to provide feedback on your profile.
All
2020
2019
2018
2017
2016
2015
2014
2013
2012
Earlier
All
2020
2019
2018
2017
2016
2015
2014
2013
2012
Earlier

2020

Extracellular Vesicles From Mesenchymal Stem Cells as a Covid-19 Treatment
2020

Human bone marrow stem/stromal cell osteogenesis is regulated via mechanically activated osteocyte-derived extracellular vesicles
2020

Mesenchymal Stem Cell Derived Extracellular Vesicles for Tissue Engineering and Regenerative Medicine Applications
2020

The future of Extracellular Vesicles as Theranostics - an ISEV meeting report
2019

2-Deoxy-D-Glucose inhibits aggressive triple-negative breast cancer cells by targeting glycolysis and the cancer stem cell phenotype
2019

Considerations towards a roadmap for collection, handling and storage of blood extracellular vesicles.
2019

Inhibiting extracellular vesicles formation and release: a review of EV inhibitors.
2019

Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines
2018

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
2018

Extracellular vesicles and anti-cancer drug resistance
2018

miR-758-3p: a blood-based biomarker that's influence on the expression of CERP/ABCA1 may contribute to the progression of obesity to metabolic syndrome.
2017

Can hi-jacking hypoxia inhibit extracellular vesicles in cancer?
2017

EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research.
2017

MicroRNA Profiling of Exosomes
2017

Neratinib-resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4
2017

Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer
2017

Profiling Circulating miRNAs from the Plasma of Individuals with Metabolic Syndrome
2017

Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles.
2017

miR-758-3p: a blood-based biomarker that's influence on the expression of CERP/ABCA1 may contribute to the progression of obesity to metabolic syndrome.
2016

Blood-based biomarkers for metabolic syndrome
2016

Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine.
2016

MicroRNA Profiling of Exosomes.
2016

Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.
2016

Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer.
2016

Profiling Circulating miRNAs from the Plasma of Individuals with Metabolic Syndrome.
2016

The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance.
2015

Analysis of changes in phosphorylation of Receptor Tyrosine Kinases: antibody arrays
2015

Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.
2015

Biological properties of extracellular vesicles and their physiological functions.
2015

Dairy proteins, dairy lipids, and postprandial lipemia in persons with abdominal obesity (DairyHealth): a 12-wk, randomized, parallel-controlled, double-blinded, diet intervention study.
2015

Expanding on Exosomes and Ectosomes in Cancer
2015

Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies.
2015

Neuromedin U to increase IL-6 levels and to expand cancer stem cells in HER2-positive breast cancer cells.
2015

Neuromedin U: a multifunctional neuropeptide with pleiotropic roles.
2015

Receptor tyrosine kinase targeting in multicellular spheroids.
2015

Receptor tyrosine kinases and drug resistance: development and characterization of in vitro models of resistance to RTK inhibitors.
2015

The Role of Exosomes in Breast Cancer.
2015

The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance.
2015

miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.
2014

Analysis of changes in phosphorylation of receptor tyrosine kinases: antibody arrays.
2014

Biological properties of extracellular vesicles and their physiological functions.
2014

Dairy proteins, dairy lipids, and postprandial lipemia in persons with abdominal obesity (DairyHealth): a 12-wk, randomized, parallel-controlled, double-blinded, diet intervention study.
2014

Exosomes are involved in mediating radiation induced bystander signaling in human keratinocyte cells.
2014

Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies.
2014

Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.
2014

Predictive biomarkers for dasatinib treatment in melanoma
2014

Receptor tyrosine kinase targeting in multicellular spheroids.
2014

Receptor tyrosine kinases and drug resistance: development and characterization of in vitro models of resistance to RTK inhibitors.
2014

miR-134 transported in extracellular vesicles reduces triple-negative breast cancer aggression.
2014

miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
2014

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
2013

3-Dimensional cell culture: the missing link in drug discovery.
2013

Assessment of neratinib-resistance and cross-resistance in HER2-overexpressing breast cancer cells.
2013

Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.
2013

Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis.
2013

EGFR and HER2 inhibition in pancreatic cancer.
2013

Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells
2013

Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma.
2013

ISEV position paper: extracellular vesicle RNA analysis and bioinformatics.
2013

ISEV position paper: extracellular vesicle RNA analysis and bioinformatics.
2013

The Relevance of exosomal-miRNAs in triple-negative breast cancer progression.
2013

The potential of miR-630, an IGF1R regulator, as a predictive biomarker for HER2-targeted drugs.
2013

Three-dimensional cell culture: The missing link in drug discovery
2013

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.
2012

Alterations in Apoptosis-related Genes in Cell Line Models of Acquired Lapatinib Resistance, Identifies Potential Therapeutic Targets for the Treatment of Lapatinib Resistant HER2-positive
2012

Can exosomes influence triple negative breast cancer metastasis?
2012

Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.
2012

EGFR and HER2 inhibition in pancreatic cancer.
2012

Effect of acquired resistance to lapatinib in HER2-positive breast cancer cells on the Bcl-2 family members MCL-1 and BAX.
2012

Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells.
2012

Exosomes: potential regulators and biomarkers of prostate cancer progression.
2012

Generation and Characterisation of Neratinib-resistant Breast Cancer Cell Line Variants.
2012

Isosteviol has beneficial effects on palmitate-induced α-cell dysfunction and gene expression.
2012

MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis.
2012

Neuromedin U: A potential predictive biomarker for HER2-targeted drugs.
2012

Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance.
2012

The relevance of exosomes in prostate cancer and their potential to confer docetaxel resistance to secondary cells.
2012

The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines
2012

Three-dimensional cell culture: the missing link in drug discovery.
2011

Analysis of gene expression as relevant to cancer cells and circulating tumour cells.
2011

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
2011

Identification of predictive biomarkers for dasatinib treatment of metastatic melanoma.
2011

Intracellular and extracellular microRNAs in breast cancer.
2011

Isolation of exosomes for subsequent mRNA, MicroRNA, and protein profiling.
2011

Isolation, structure elucidation, and cytotoxic evaluation of furanonaphthoquinones from in vitro plantlets and cultures of Streptocarpus dunnii.
2011

MicroRNA expression analysis: techniques suitable for studies of intercellular and extracellular microRNAs.
2011

Reverse-transcriptase polymerase chain reaction to detect extracellular mRNAs.
2011

Triple-negative Breast Cancer Cells May Transfer Phenotypic Characteristics via Exosomes.
2011

Western blotting analysis as a tool to study receptor tyrosine kinases.
2011

microRNAs-key contributors to endocrinology.
2010

Decreasing Txnip mRNA and protein levels in pancreatic MIN6 cells reduces reactive oxygen species and restores glucose regulated insulin secretion.
2010

Identification of microRNAs with a role in glucose stimulated insulin secretion by expression profiling of MIN6 cells.
2010

Intracellular and extracellular microRNAs in breast cancer.
2010

Isolation, structure elucidation, and cytotoxic evaluation of furanonaphthoquinones from in vitro plantlets and cultures of Streptocarpus dunnii.
2010

MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis.
2010

Melanoma-associated antigen family protein-D4: clinical significance and functional relevance in breast cancer
2010

Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis
2010

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer.
2009

Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine.
2009

Current Cancer Drug Targets
2009

Expression of multidrug resistance markers ABCB1 (MDR-1/ Pgp) and ABCC1 (MRP-1) in renal cell carcinoma
2009

Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal carcinoma
2009

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer.
2009

TMEM25, REPS2 and Meis 1: favourable prognostic and predictive biomarkers for breast cancer.
2009

Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
2008

Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue.
2008

Feasibility and relevance of global expression profiling of gene transcripts in serum from breast cancer patients using whole genome microarrays and quantitative RT-PCR.
2008

Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines.
2008

Molecular medicine of microRNAs: structure, function and implications for diabetes
2008

Prevalence and prognostic and predictive relevance of PRAME in breast cancer
2008

Proteomic analysis of conditioned media from glucose responsive and glucose non-responsive phenotypes reveals a panel of secreted proteins associated with beta cell dysfunction.
2008

SNIP/p140Cap mRNA expression is an unfavourable prognostic factor in breast cancer and is not expressed in normal breast tissue.
2007

2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins.
2007

A microarray approach to translational medicine in breast cancer: how representative are cell line models of clinical conditions?
2007

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
2007

Detecting de novo insulin synthesis in embryonic stem cell-derived populations.
2007

Detection of amplifiable mRNA extracellular to insulin-producing cells: potential for predicting beta cell mass and function.
2007

Directed differentiation of mouse embryonic stem cells into pancreatic-like or neuronal- and glial-like phenotypes.
2007

Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue.
2007

Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
2007

Extracellular nucleic acids and their potential as diagnostic, prognostic and predictive biomarkers.
2007

Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines.
2007

MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma.
2007

MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer.
2007

Prevalence and prognostic and predictive relevance of PRAME in breast cancer.
2007

The emerging world of microRNAs.
2006

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
2006

Biomarkers and multiple drug resistance in breast cancer.
2006

Detecting de novo insulin synthesis in embryonic stem cell-derived populations.
2006

Evaluation of recombinant human transferrin (DeltaFerrin(TM)) as an iron chelator in serum-free media for mammalian cell culture.
2006

Gene Expression Microarray Technology: Some Applications in Lung Cancer Research.
2006

Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays.
2006

Methods in Apoptosis
2006

Molecular markers of multiple drug resistance in breast cancer.
2006

Phenotypic and global gene expression profile changes between low passage and high passage MIN-6 cells.
2006

Proteomic screening of glucose-responsive and glucose non-responsive MIN-6 beta cells reveals differential expression of proteins involved in protein folding, secretion and oxidative stress.
2006

Setting up a Cell Culture Laboratory
2006

The development and validation of the Virtual Tissue Matrix, a software application that facilitates the review of tissue microarrays on line.
2006

The emerging world of microRNAs.
2005

Detection of Specific mRNAs in Culture Medium Conditioned by Human Tumour Cells: Potential for New Class of Cancer Biomarkers in Serum.
2005

Evaluation of recombinant human transferrin (DeltaFerrin(TM)) as an iron chelator in serum-free media for mammalian cell culture.
2005

Molecular markers of multiple drug resistance in breast cancer.
2005

The development and validation of the Virtual Tissue Matrix, a software application that facilitates the review of tissue microarrays on line.
2004

Detection of Specific mRNAs in Culture Medium Conditioned by Human Tumour Cells: Potential for New Class of Cancer Biomarkers in Serum.
2004

Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs.
2004

Expression and prognostic relevance of Mcl-1 in breast cancer.
2004

Expression in murine teratocarcinoma F9 cells of transcription factors involved in pancreas development.
2004

Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study.
2004

Mechanisms associated with loss of glucose responsiveness in beta cells.
2003

Challenges in molecular analysis for individualized cancer therapy.
2003

Characterisation of BHK-21 cells engineered to secrete human insulin.
2003

Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro.
2003

Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer.
2003

Prognostic importance of survivin in breast cancer.
2003

Survivin: role in normal cells and in pathological conditions.
2002

Engineering Vero cells to secrete human insulin.
2002

Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro.
1997

Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance.
1997

Matrix metalloproteinase expression and production by alveolar macrophages in emphysema.
1996

Multiple drug resistance-related messenger RNA expression in archival formalin-fixed paraffin-embedded human breast tumour tissue.
1996

mdr1 ribozyme mediated reversal of the multi-drug resistant phenotype in human lung cell lines.
1995

Multiple drug resistance in variants of a human lung cell line exposed to adriamycin and VP-16.
1994

Investigation of mechanisms of multiple drug resistance using polymerase chain reaction
1993

The use of reverse transcriptase-polymerase chain reaction (RT-PCR) to investigate specific gene expression in multidrug-resistant cells.

These arethe10 unique sources for Lorraine O'Driscoll's 164 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.

Source #
Ireland -> Dublin City University 47
Ireland -> Dublin City University -> PubMed 43
Ireland -> Dublin Institute of Technology 1
Ireland -> Dublin Institute of Technology -> PubMed 1
Ireland -> Maynooth University 5
Ireland -> Trinity College Dublin 146
Ireland -> Trinity College Dublin -> PubMed 34
Ireland -> University College Dublin 1
Ireland -> University College Dublin -> PubMed 1
Ireland -> University of Limerick 1
Nov 6, 2008

DIAGNOSTIC, PROGNOSTIC AND/OR PREDICTIVE INDICATORS OF BREAST CANCER
+

  1. Further insights

    Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.

  2. Details

    Here is a quick breakdown of this expert's publication history

  3. Contact

    If this is the expert you have been looking for, simply click here to make contact.